Radiodermatitis Market Size, Share & Trends Analysis Report By Product (Topical, Corticosteroids, Hydrophilic Creams, Antibiotics, Dressings, Hydrogel & Hydrocolloid), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global radiodermatitis market size was estimated at USD 412.6 million in 2022 and is anticipated to expand at a CAGR of 3.9% from 2023 to 2030. The market is predominantly driven by a growing number of patients suffering from radiodermatitis as an adverse effect of radiation therapy. The need for radiodermatitis treatment items is now more urgent than it has ever been because of the need to stop this negative consequence. Radiodermatitis, which includes erythema, dry desquamation, and moist desquamation, affects 95% of cancer patients getting radiation therapy. Also, it is estimated that 85-95% of patients receiving radiotherapy for breastcancer experience radiodermatitis in variable degrees.

The COVID-19 pandemic has disrupted the radiodermatitis market in the initial phase. Treatment of cancer patients in the radiation oncology departments during the pandemic was challenging as the priority of the healthcare institutions was COVID-19 patients.In comparison to the same months in 2019, the weekly radiation sessions decreased by 19.9% in April, 6.2% in May, and 11.6% in June of 2020. However, the ease in lockdown and restriction in various regions and appropriate and safest cancer treatment initiatives by the cancer institutes has created growth opportunities for the market post-Covid-19 crisis.

As the prevalence of diabetes and obesity increases, the cases of cancer are also rising. According to the Centers for Disease Control, there were 34.2 million cases of diabetes worldwide in 2018; this number is expected to climb to 1.2 billion by 2030. This increase will show that a greater population of patients are more likely to get cancer, and because of a co-morbid condition, they would be more prone to experience radiation-induced skin damage. This is likely to drive the market during the forecast period.

One of the key factors driving this market is the growing number of governmental and private healthcare organisations actively working to raise knowledge about the management and treatment of radiodermatitis. These organisations also publish instructions and suggestions for effectively treating the illness, which is expected to increase the potential for growth throughout the course of the projection period.

For instance, the Provincial Health Services Authority's BC Cancer Agency published information on radiodermatitis risk factors as well as instructions for managing the symptoms of the condition. This is expected to increase knowledge of assessment & treatment methods as well as general skincare advice, boosting potential growth. The product pipeline is expected to grow and the market will have profitable growth opportunities as more clinical studies are conducted to assess the effectiveness of a variety of radiodermatitis treatment products for treatment.

Product Insights

The topical product segment, with a share of nearly 71.3%, had the biggest market share in 2022. The significant portion is thought to result from the advantages of topical products. These advantages, which are some of the primary driving forces for the acceptance of these items throughout the previous years, include ease of use, accessibility, and great cost-efficiency. Additionally, topical products lessen the chance of microbiological transmission and protect the skin from abrasives substances. Some of the key items under this category are topical antibiotics, hydrophilic lotions, and corticosteroids. Due to their reputation as the gold standard in the treatment of inflammatory skin disorders, which prompted their adoption for the treatment of radiodermatitis, corticosteroids accounted for the biggest proportion among topical agents.

Dressings are anticipated to attain moderate growth rate over the coming years owing to the presence of a wide array of products in the market. These products include foam-based, hydrogel & hydrocolloid, silicone-coated, silver-leaf dressings, and others. Dressings have been found to be sufficient for effective treatment of various grades of radiation burns, which is anticipated to fuel their adoption over the coming years. Because of the advantages, hydrogel and hydrocolloid dressings are being used more frequently to treat radiation burns. These advantages include quick healing, little discomfort, and high levels of protection against infection and bacterial growth. Future growth opportunities for this market segment are also anticipated to be expanded by the accessibility of a wide range of these items, each of which caters to a different set of patient needs.

Distribution Channel Insights

In 2022, retail pharmacies had the greatest share of the distribution channel segment, accounting for 39.3%. The significant percentage can be attributable to retail stores' high accessibility and cost. Drug cost reimbursement encourages patients to rely on retail pharmacies, which increases market growth potential as a result of affordability.

Due to numerous benefits, including more convenience for customers who don't want to buy medications from retail or hospital pharmacies, online pharmacies are expected to see exponential growth rates throughout the course of the projection period. Furthermore, there is a gap between the supply and demand of very important pharmaceuticals as a result of the increasing frequency of chronic diseases. Through the course of the projected period, these factors will increase demand for online pharmacies. With the help of online pharmacies, order procurement and tracking by the customer becomes convenient. In addition, associated supply chain management (SCM) eliminates some of the market intermediaries, which reduces the overall drug price, hence driving the inclination of customers toward online medicine purchases.

Regional Insights

Asia Pacific dominated the market and accounted for 46.0% in 2022. The growing number of cancer patients in this area is a major factor in the significant share that this area has managed to gain. The larger share that this region has acquired is also due to substantial collaborations made by key businesses to increase their product range expansion capabilities. Additionally, well-known pharmaceutical firms in this region are heavily involved in the sales of their goods and the promotion of end-user adoption. Key growth drivers for this region include favorable government efforts that boost research activity and an increase in outsourcing by industrialized economies.

North America held the second-largest share of the market. This market is predominantly driven by high R&D investment deployed by global players and their focus to attain a competitive position in the market. In addition, high disposable income, and the presence of sophisticated healthcare infrastructure are responsible for the significant growth opportunities across the region.

Key Companies & Market Share Insights

Key players employ sustainability initiatives widely in the competitive context. The market for radiodermatitis is dominated by the four largest competitors, 3M Healthcare, ConvaTec, Inc., Mölnlycke Health Care AB, and Smith & Nephew together. These businesses continuously priorities tactics like mergers and acquisitions, new product development projects, and regional expansion. For instance, In March 2022, Convatec Group Plc announced the acquisition of Triad Life Sciences Inc. The acquisition enhances the company’s advanced wound management and patient outcomes. Furthermore, CIVCO Radiotherapy and Stratpharma AG collaborated in April 2019 to intensify their focus on wound care for radiation therapy patients. CIVCO Radiotherapy is a specialist in offering top-notch, patient-focused radioactive solutions. This is likely to focus on patient centric care and improve post procedure outcomes. Some of the prominent players in the global radiodermatitis market include:

• Stratpharma AG

• Smith & Nephew

• Molnlycke Health Care AB

• Derma Sciences Inc.

• ConvaTec Inc.

• BMG Pharma S.R.L.

• Acelity

• 3M

• Alliqua BioMedical

Radiodermatitis Market Report Scope

Global Radiodermatitis Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global radiodermatitis market report on the basis of product, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Topical

    • Corticosteroids

    • Hydrophilic creams

    • Antibiotics

    • Others

  • Oral

  • Dressings

    • Hydrogel & Hydrocolloid dressings

    • No Sting Barrier Film

    • Honey-Impregnated Gauze

    • Silicone Coated Dressings

    • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Mexico

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait